Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010 Apr; 17(4):1159-67.